AptarGroup (ATR)
Market Price (8/23/2026): $134.8 | Market Cap: $8.6 BilSector: Materials | Industry: Metal, Glass & Plastic Containers
AptarGroup (ATR)
Market Price (8/23/2026): $134.8Market Cap: $8.6 BilSector: MaterialsIndustry: Metal, Glass & Plastic Containers
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Attractive yieldTotal YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 5.7% Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 15% Low stock price volatilityVol 12M is 25% Megatrend and thematic driversMegatrends include Circular Economy & Recycling, Sustainable Consumption, and Precision Medicine. Themes include Sustainable Packaging Materials, Show more. | Weak multi-year price returns2Y Excs Rtn is -44%, 3Y Excs Rtn is -59% | Key risksATR key risks include [1] a significant, Show more. |
| Attractive yieldTotal YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 5.7% |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 15% |
| Low stock price volatilityVol 12M is 25% |
| Megatrend and thematic driversMegatrends include Circular Economy & Recycling, Sustainable Consumption, and Precision Medicine. Themes include Sustainable Packaging Materials, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -44%, 3Y Excs Rtn is -59% |
| Key risksATR key risks include [1] a significant, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Updated on 8/1/2026
AptarGroup (ATR) stock has gained about 10% since 4/30/2026 because of the following key factors:
1. AptarGroup reported record revenue and beat earnings estimates for fiscal Q2 2026.
The company's reported sales increased 6% to $1.03 billion for the fiscal second quarter ended June 30, 2026, marking the first time quarterly revenue surpassed $1 billion. Additionally, AptarGroup's adjusted earnings per share of $1.42 for fiscal Q2 2026 exceeded Wall Street's consensus estimate of $1.36.
2. The Pharma segment demonstrated robust growth, and the company issued optimistic fiscal Q3 2026 guidance.
Aptar Pharma was a primary driver of growth in fiscal Q2 2026, with double-digit increases in consumer healthcare and high single-digit growth in injectables and prescription products, excluding emergency medicine. Management projected adjusted earnings per share for fiscal Q3 2026 to be between $1.45 and $1.53, indicating confidence in continued growth across all three segments.
Show more
AptarGroup (ATR) stock has gained about 10% since 4/30/2026 because of the following key factors:
1. AptarGroup reported record revenue and beat earnings estimates for fiscal Q2 2026.
The company's reported sales increased 6% to $1.03 billion for the fiscal second quarter ended June 30, 2026, marking the first time quarterly revenue surpassed $1 billion. Additionally, AptarGroup's adjusted earnings per share of $1.42 for fiscal Q2 2026 exceeded Wall Street's consensus estimate of $1.36.
2. The Pharma segment demonstrated robust growth, and the company issued optimistic fiscal Q3 2026 guidance.
Aptar Pharma was a primary driver of growth in fiscal Q2 2026, with double-digit increases in consumer healthcare and high single-digit growth in injectables and prescription products, excluding emergency medicine. Management projected adjusted earnings per share for fiscal Q3 2026 to be between $1.45 and $1.53, indicating confidence in continued growth across all three segments.
Show more
Updated on 8/1/2026
AptarGroup (ATR) stock has gained about 10% since 4/30/2026 because of the following key factors:
1. AptarGroup reported record revenue and beat earnings estimates for fiscal Q2 2026.
The company's reported sales increased 6% to $1.03 billion for the fiscal second quarter ended June 30, 2026, marking the first time quarterly revenue surpassed $1 billion. Additionally, AptarGroup's adjusted earnings per share of $1.42 for fiscal Q2 2026 exceeded Wall Street's consensus estimate of $1.36.
2. The Pharma segment demonstrated robust growth, and the company issued optimistic fiscal Q3 2026 guidance.
Aptar Pharma was a primary driver of growth in fiscal Q2 2026, with double-digit increases in consumer healthcare and high single-digit growth in injectables and prescription products, excluding emergency medicine. Management projected adjusted earnings per share for fiscal Q3 2026 to be between $1.45 and $1.53, indicating confidence in continued growth across all three segments.
3. Analyst sentiment improved with several rating upgrades and increased price targets.
Multiple analyst firms upgraded AptarGroup's rating or raised their price targets between May and July 2026, contributing to a consensus "Moderate Buy" rating with an average target price of $170.80. For example, Bank of America upgraded the stock from "neutral" to "buy" with a $173.00 price objective on July 14, 2026.
4. Shareholder returns were enhanced through significant share repurchases and consistent dividends.
AptarGroup returned $81 million to shareholders in fiscal Q2 2026 through share repurchases and dividends. Specifically, the company repurchased 403,000 shares for $50 million during the fiscal second quarter. A quarterly cash dividend of $0.48 per share was also declared, payable on August 20, 2026.
Show less
AptarGroup (ATR) stock has gained about 10% since 4/30/2026 because of the following key factors:
1. AptarGroup reported record revenue and beat earnings estimates for fiscal Q2 2026.
The company's reported sales increased 6% to $1.03 billion for the fiscal second quarter ended June 30, 2026, marking the first time quarterly revenue surpassed $1 billion. Additionally, AptarGroup's adjusted earnings per share of $1.42 for fiscal Q2 2026 exceeded Wall Street's consensus estimate of $1.36.
2. The Pharma segment demonstrated robust growth, and the company issued optimistic fiscal Q3 2026 guidance.
Aptar Pharma was a primary driver of growth in fiscal Q2 2026, with double-digit increases in consumer healthcare and high single-digit growth in injectables and prescription products, excluding emergency medicine. Management projected adjusted earnings per share for fiscal Q3 2026 to be between $1.45 and $1.53, indicating confidence in continued growth across all three segments.
3. Analyst sentiment improved with several rating upgrades and increased price targets.
Multiple analyst firms upgraded AptarGroup's rating or raised their price targets between May and July 2026, contributing to a consensus "Moderate Buy" rating with an average target price of $170.80. For example, Bank of America upgraded the stock from "neutral" to "buy" with a $173.00 price objective on July 14, 2026.
4. Shareholder returns were enhanced through significant share repurchases and consistent dividends.
AptarGroup returned $81 million to shareholders in fiscal Q2 2026 through share repurchases and dividends. Specifically, the company repurchased 403,000 shares for $50 million during the fiscal second quarter. A quarterly cash dividend of $0.48 per share was also declared, payable on August 20, 2026.
Show less
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →
Stock Movement Drivers
Fundamental Drivers
The 9.8% change in ATR stock from 4/30/2026 to 8/22/2026 was primarily driven by a 16.5% change in the company's P/E Multiple.| (LTM values as of) | 4302026 | 8222026 | Change |
|---|---|---|---|
| Stock Price ($) | 122.76 | 134.80 | 9.8% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 3,777 | 3,933 | 4.1% |
| Net Income Margin (%) | 10.4% | 9.2% | -11.4% |
| P/E Multiple | 20.3 | 23.7 | 16.5% |
| Shares Outstanding (Mil) | 65 | 64 | 2.1% |
| Cumulative Contribution | 9.8% |
Market Drivers
4/30/2026 to 8/22/2026| Return | Correlation | |
|---|---|---|
| ATR | 9.8% | |
| Market (SPY) | 6.5% | 6.4% |
| Sector (XLB) | 4.0% | 48.0% |
Fundamental Drivers
The 9.1% change in ATR stock from 1/31/2026 to 8/22/2026 was primarily driven by a 22.2% change in the company's P/E Multiple.| (LTM values as of) | 1312026 | 8222026 | Change |
|---|---|---|---|
| Stock Price ($) | 123.54 | 134.80 | 9.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 3,663 | 3,933 | 7.4% |
| Net Income Margin (%) | 11.5% | 9.2% | -19.5% |
| P/E Multiple | 19.4 | 23.7 | 22.2% |
| Shares Outstanding (Mil) | 66 | 64 | 3.3% |
| Cumulative Contribution | 9.1% |
Market Drivers
1/31/2026 to 8/22/2026| Return | Correlation | |
|---|---|---|
| ATR | 9.1% | |
| Market (SPY) | 11.0% | 33.1% |
| Sector (XLB) | 9.2% | 59.6% |
Fundamental Drivers
The -12.9% change in ATR stock from 7/31/2025 to 8/22/2026 was primarily driven by a -14.6% change in the company's P/E Multiple.| (LTM values as of) | 7312025 | 8222026 | Change |
|---|---|---|---|
| Stock Price ($) | 154.80 | 134.80 | -12.9% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 3,555 | 3,933 | 10.6% |
| Net Income Margin (%) | 10.4% | 9.2% | -11.5% |
| P/E Multiple | 27.7 | 23.7 | -14.6% |
| Shares Outstanding (Mil) | 66 | 64 | 4.1% |
| Cumulative Contribution | -12.9% |
Market Drivers
7/31/2025 to 8/22/2026| Return | Correlation | |
|---|---|---|
| ATR | -12.9% | |
| Market (SPY) | 22.2% | 23.5% |
| Sector (XLB) | 23.8% | 50.8% |
Fundamental Drivers
The 15.4% change in ATR stock from 7/31/2023 to 8/22/2026 was primarily driven by a 24.4% change in the company's Net Income Margin (%).| (LTM values as of) | 7312023 | 8222026 | Change |
|---|---|---|---|
| Stock Price ($) | 116.83 | 134.80 | 15.4% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 3,389 | 3,933 | 16.1% |
| Net Income Margin (%) | 7.4% | 9.2% | 24.4% |
| P/E Multiple | 30.5 | 23.7 | -22.4% |
| Shares Outstanding (Mil) | 66 | 64 | 3.0% |
| Cumulative Contribution | 15.4% |
Market Drivers
7/31/2023 to 8/22/2026| Return | Correlation | |
|---|---|---|
| ATR | 15.4% | |
| Market (SPY) | 73.2% | 43.0% |
| Sector (XLB) | 31.8% | 55.7% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| ATR Return | -10% | -9% | 14% | 29% | -21% | 10% | 5% |
| Peers Return | 20% | -8% | 6% | -1% | -5% | 20% | 33% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 12% | 103% |
Monthly Win Rates [3] | |||||||
| ATR Win Rate | 42% | 42% | 67% | 83% | 50% | 50% | |
| Peers Win Rate | 65% | 42% | 52% | 50% | 53% | 62% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| ATR Max Drawdown | -27% | -24% | -9% | -11% | -30% | -23% | |
| Peers Max Drawdown | -15% | -33% | -24% | -22% | -27% | -22% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: WST, SLGN, AMCR, CCK, SON. See ATR Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 8/21/2026 (YTD)
How Low Can It Go
| Event | ATR | S&P 500 |
|---|---|---|
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -21.9% | -24.5% |
| % Gain to Breakeven | 28.1% | 32.4% |
| Time to Breakeven | 142 days | 427 days |
| 2020 COVID-19 Crash | ||
| % Loss | -27.0% | -33.7% |
| % Gain to Breakeven | 37.0% | 50.9% |
| Time to Breakeven | 101 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -17.2% | -19.2% |
| % Gain to Breakeven | 20.8% | 23.8% |
| Time to Breakeven | 88 days | 105 days |
| 2014-2016 Oil Price Collapse | ||
| % Loss | -12.4% | -6.8% |
| % Gain to Breakeven | 14.2% | 7.3% |
| Time to Breakeven | 25 days | 15 days |
| 2011 US Debt Ceiling Crisis & European Contagion | ||
| % Loss | -19.0% | -17.9% |
| % Gain to Breakeven | 23.4% | 21.8% |
| Time to Breakeven | 81 days | 123 days |
| 2010 Eurozone Sovereign Debt Crisis / Flash Crash | ||
| % Loss | -13.4% | -15.4% |
| % Gain to Breakeven | 15.4% | 18.2% |
| Time to Breakeven | 20 days | 125 days |
In The Past
AptarGroup's stock fell -9.1% during the 2025 US Tariff Shock. Such a loss loss requires a 10.0% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | ATR | S&P 500 |
|---|---|---|
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -21.9% | -24.5% |
| % Gain to Breakeven | 28.1% | 32.4% |
| Time to Breakeven | 142 days | 427 days |
| 2020 COVID-19 Crash | ||
| % Loss | -27.0% | -33.7% |
| % Gain to Breakeven | 37.0% | 50.9% |
| Time to Breakeven | 101 days | 140 days |
| 2008-2009 Global Financial Crisis | ||
| % Loss | -40.2% | -53.4% |
| % Gain to Breakeven | 67.3% | 114.4% |
| Time to Breakeven | 401 days | 1085 days |
In The Past
AptarGroup's stock fell -9.1% during the 2025 US Tariff Shock. Such a loss loss requires a 10.0% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About AptarGroup (ATR)
AptarGroup (ATR) is a global leader in providing innovative dispensing, sealing, and material science solutions. The company designs and manufactures a wide range of sophisticated packaging components that enable precise and controlled delivery of products across numerous consumer and healthcare applications. Essentially, AptarGroup helps brand owners deliver their products effectively and safely to end-users through its specialized engineering and manufacturing capabilities.
The company operates through three primary segments, each serving distinct markets with tailored products. Its Pharma segment offers critical components like metered dose inhaler valves for respiratory ailments, pumps for nasal allergy treatments, and injectable primary packaging components for prescription drugs, consumer healthcare, and injectable markets. The Beauty + Home segment supplies pumps, closures, aerosol valves, accessories, and decorative components primarily for beauty, personal care, and home care products. Lastly, the Food + Beverage segment provides a variety of dispensing and non-dispensing closures, elastomeric flow control components, and spray pumps for the food and beverage industries.
AptarGroup serves a diverse global customer base through its own sales force and a network of independent representatives and distributors across North America, Europe, Asia, and Latin America. The company also emphasizes innovation and sustainability, engaging in strategic partnerships to develop ultra-pure recycled materials for its applications and collaborating on digital therapy platforms to enhance solutions in the healthcare space.
AI Analysis | Feedback
Here are a couple of analogies to describe AptarGroup (ATR):
-
AptarGroup is like the Intel Inside for the caps, pumps, and spray nozzles on countless everyday products, from personal care items to prescription medications.
-
They are similar to 3M, but specifically focused on engineered dispensing, sealing, and material science solutions for products ranging from shampoo to nasal allergy sprays and food packaging.
AI Analysis | Feedback
- Dispensing Pumps: Components that facilitate controlled dispensing of liquids, used in pharmaceuticals, beauty, personal care, and food/beverage products.
- Closures: A variety of dispensing and non-dispensing caps and tops for packaging in food, beverage, personal care, and home care markets.
- Aerosol Valves: Essential mechanisms for delivering products in aerosol form, found in beauty, home care, food, and beverage applications.
- Metered Dose Inhaler Valves: Specialized valves that deliver precise dosages of medication for respiratory ailments, such as asthma and COPD.
- Injectable Primary Packaging Components: Elastomeric components used in pharmaceutical packaging for injectable drugs.
- Active Material Science Solutions: Innovative solutions that incorporate advanced materials to enhance product performance, protection, or delivery, particularly in pharmaceutical applications.
- Elastomeric Flow Control Components: Flexible components designed to regulate or control the flow of liquids, primarily within the food and beverage industry.
- Sealing Solutions: Products designed to create effective seals for various packaging, ensuring product integrity and preventing leakage.
AI Analysis | Feedback
AptarGroup (ATR) sells its products primarily to other companies (Business-to-Business or B2B) rather than directly to individuals.
Based on the provided background information, the specific names of AptarGroup's major customer companies are not disclosed. However, the company provides its dispensing, sealing, and material science solutions to manufacturers and brands across several key markets:
- Pharmaceutical Companies: These customers utilize Aptar's solutions for prescription drugs, consumer health care products, and injectables, including pumps for nasal allergy treatments, metered dose inhaler valves for respiratory ailments, and elastomer for injectable primary packaging components.
- Beauty, Personal Care, and Home Care Brands: Aptar supplies these customers with pumps, closures, aerosol valves, accessories, and sealing solutions for a wide range of products such as cosmetics, perfumes, lotions, shampoos, body washes, and household cleaning products.
- Food and Beverage Manufacturers: For this market, Aptar offers dispensing and non-dispensing closures, elastomeric flow control components, spray pumps, and aerosol valves used in various food and beverage products.
AI Analysis | Feedback
```html
- PureCycle Technologies LLC (NASDAQ: PCT)
AI Analysis | Feedback
Stephan B. Tanda, President and Chief Executive Officer
Prior to joining Aptar in February 2017, Mr. Tanda served as an Executive Managing Board Director at Royal DSM NV, overseeing its global Nutrition business and Pharma joint ventures and business interests in the Americas. His career spans over 25 years, during which he lived and worked in seven countries, holding leadership roles at DuPont and as President and CEO of Freudenberg Nonwovens Group. He has experience in developing organizations and businesses, achieving sales and profit growth through both organic means and acquisitions. Mr. Tanda also served as a director of Patheon NV, a pharmaceutical development and manufacturing services company, which was sold to Thermo Fisher Scientific in 2017.
Vanessa Kanu, Executive Vice President and Chief Financial Officer
Ms. Kanu became Aptar's Executive Vice President and Chief Financial Officer on January 1, 2025. She brings over 25 years of experience with global multi-billion dollar and publicly traded companies. Most recently, she served as CFO of TELUS International, where she led the largest technology IPO in the history of the Toronto Stock Exchange and was involved in the acquisition and integration of several strategic acquisitions. She previously held the CFO role at Mitel Networks Corporation. Ms. Kanu also serves on the Board of Directors of Manulife Financial Corporation.
Gael Touya, President, Aptar Pharma
Mr. Touya was named President of Aptar Pharma in September 2018. He has over 30 years of experience with Aptar, having served as President of the Food + Beverage segment and overseeing its European operations prior to his current role. He has held various sales, business development, and general manager positions across all of Aptar's business segments in Europe and Asia, including a multi-year assignment in China.
Marc Prieur, President, Aptar Beauty
Mr. Prieur was appointed President of Aptar Beauty in December 2019. His career with Aptar spans over 20 years, during which he has lived and worked in Europe, the United States, and China. His experience includes leadership roles in Sales & Operations for Consumer Health Care in Europe and Aptar's Pharma business in Asia. He also previously served as President of Aptar Food + Beverage and as Vice President of Operational Excellence for the company.
Xiangwei Gong, Executive Vice President, Strategic Group Development and President, Aptar Asia
Ms. Gong joined Aptar in October 2018 as President, Aptar Asia. She is an entrepreneurial leader with over 25 years of experience in B2B and B2C businesses, with a strong background in the Beauty, Personal Care, Nutrition, and Pharma industries. She has lived and worked in several countries, holding increasingly senior roles at Roche Vitamins and Royal DSM.
Prior to joining Aptar in February 2017, Mr. Tanda served as an Executive Managing Board Director at Royal DSM NV, overseeing its global Nutrition business and Pharma joint ventures and business interests in the Americas. His career spans over 25 years, during which he lived and worked in seven countries, holding leadership roles at DuPont and as President and CEO of Freudenberg Nonwovens Group. He has experience in developing organizations and businesses, achieving sales and profit growth through both organic means and acquisitions. Mr. Tanda also served as a director of Patheon NV, a pharmaceutical development and manufacturing services company, which was sold to Thermo Fisher Scientific in 2017.
Vanessa Kanu, Executive Vice President and Chief Financial Officer
Ms. Kanu became Aptar's Executive Vice President and Chief Financial Officer on January 1, 2025. She brings over 25 years of experience with global multi-billion dollar and publicly traded companies. Most recently, she served as CFO of TELUS International, where she led the largest technology IPO in the history of the Toronto Stock Exchange and was involved in the acquisition and integration of several strategic acquisitions. She previously held the CFO role at Mitel Networks Corporation. Ms. Kanu also serves on the Board of Directors of Manulife Financial Corporation.
Gael Touya, President, Aptar Pharma
Mr. Touya was named President of Aptar Pharma in September 2018. He has over 30 years of experience with Aptar, having served as President of the Food + Beverage segment and overseeing its European operations prior to his current role. He has held various sales, business development, and general manager positions across all of Aptar's business segments in Europe and Asia, including a multi-year assignment in China.
Marc Prieur, President, Aptar Beauty
Mr. Prieur was appointed President of Aptar Beauty in December 2019. His career with Aptar spans over 20 years, during which he has lived and worked in Europe, the United States, and China. His experience includes leadership roles in Sales & Operations for Consumer Health Care in Europe and Aptar's Pharma business in Asia. He also previously served as President of Aptar Food + Beverage and as Vice President of Operational Excellence for the company.
Xiangwei Gong, Executive Vice President, Strategic Group Development and President, Aptar Asia
Ms. Gong joined Aptar in October 2018 as President, Aptar Asia. She is an entrepreneurial leader with over 25 years of experience in B2B and B2C businesses, with a strong background in the Beauty, Personal Care, Nutrition, and Pharma industries. She has lived and worked in several countries, holding increasingly senior roles at Roche Vitamins and Royal DSM.
AI Analysis | Feedback
The key risks to AptarGroup's business include significant headwinds in its Pharma segment, particularly concerning emergency medicine products, ongoing margin volatility and operational disruptions within its Beauty + Home and Food + Beverage segments, and broad exposure to geopolitical, tariff, and foreign exchange risks inherent in its global operations.
-
Headwinds in the Pharma Segment, especially Emergency Medicine: AptarGroup faces a substantial risk due to a decline in demand for emergency medicine products, which are a highly profitable part of its Pharma segment. This is projected to result in a significant revenue headwind for 2026, with an anticipated 35% reduction in revenues from such products and a $65 million revenue drag for the year, primarily affecting the first half. The impact is exacerbated by inventory destocking by customers. While the Pharma segment remains dominant in high-margin areas like nasal drug delivery and injectables, this specific downturn is a notable challenge to the company's profitability and growth.
-
Margin Volatility and Operational Disruptions in Beauty + Home and Food + Beverage Segments: The company's profitability has been impacted by less favorable product mix, higher production costs, environmental upgrades at facilities, and unscheduled equipment maintenance, particularly within its Beauty + Home (referred to as Beauty and Closures in some reports) and Food + Beverage (Closures) segments. These operational disruptions and cost pressures have contributed to adjusted EBITDA margin declines and are expected to continue creating headwinds, though management anticipates some abatement in the first half of 2026.
-
Geopolitical, Tariff, and Foreign Exchange Risks: With over 50% of its revenue derived internationally, AptarGroup is highly susceptible to global trade policies, tariffs, currency fluctuations, and export controls on drug delivery technologies. The imposition of significant tariffs, potential retaliatory measures, and general global trade tensions could lead to increased costs for raw materials, disrupt supply chains, and reduce demand for its products. Additionally, movements in exchange rates, particularly for major currencies like the Euro, Chinese Yuan, and Brazilian Real, can materially impact the company's financial results. Geopolitical conflicts also pose an indirect risk by affecting customer demand and supply chain stability.
AI Analysis | Feedback
null
AI Analysis | Feedback
AptarGroup, Inc. (ATR) provides a diverse range of dispensing, sealing, and material science solutions across three primary segments: Pharma, Beauty + Home, and Food + Beverage. The addressable markets for their main products and services are substantial globally.
Pharma Segment
- Nasal Spray Pumps and Nasal Drug Delivery Technology: The global nasal drug delivery technology market was valued at USD 71.9 billion in 2023 and is estimated to grow at a 6.8% CAGR from 2024 to 2032, reaching USD 129.5 billion by 2032. Specifically, the global nasal spray market was valued at USD 25.76 billion in 2024 and is expected to reach USD 43.29 billion by 2032. The global sterile nasal spray pump market size is anticipated to be worth USD 0.11 billion in 2026 and is expected to reach USD 0.16 billion by 2035.
- Metered Dose Inhaler Valves: The global metered dose inhalers market size was valued at USD 10.1 billion in 2024 and is projected to reach USD 18.4 billion by 2034. Another estimate indicates the global metered dose inhalers market size is expected to grow from USD 26.22 billion in 2024 to USD 42.02 billion by 2035.
- Injectable Primary Packaging Components: The global injectable drug packaging market was valued at USD 32 billion in 2024 and is projected to reach USD 52 billion by 2033. The broader global primary pharmaceutical packaging market was estimated at USD 105.88 billion in 2023 and is projected to reach USD 206.03 billion by 2030.
Beauty + Home Segment
- Beauty and Personal Care Packaging (Pumps, Closures, Aerosol Valves): The global beauty and personal care packaging market is projected to grow from USD 41.3 billion in 2025 to USD 87.5 billion by 2035, at a CAGR of 7.8%. In 2025, plastics held 41.12% of the personal care packaging market share.
- Home Care Packaging (Pumps, Closures, Aerosol Valves): The global home care packaging market, valued at USD 40.87 billion in 2025, is anticipated to reach USD 71.75 billion by 2035.
- Aerosol Valves (across various applications including personal care and home care): The global aerosol valves market size was estimated at USD 1.64 billion in 2024 and is expected to grow to USD 2.86 billion in 2030. Another source indicates a market size of USD 1.93 billion in 2025, forecasted to reach USD 2.36 billion by 2031. Europe dominated this market in 2024, accounting for over 27.0% of the revenue. North America is also a significant market, holding approximately 40% of the global market share.
Food + Beverage Segment
- Dispensing and Non-Dispensing Closures: The global caps and closures market size was estimated at USD 111.01 billion in 2025 and is expected to reach USD 167.41 billion by 2033. The food segment held the largest revenue share of over 26.45% in 2025 within this market. Specifically for food, the global closures for food market was valued at USD 12.5 billion in 2024 and is projected to reach USD 18.7 billion by 2033. The global beverage caps and closures market is worth USD 51.22 billion in 2025 and is forecast to hit USD 63.40 billion by 2030.
- Aerosol Valves (for food and beverage markets): The global aerosol valves market, which includes food and beverage applications, was estimated at USD 1.64 billion in 2024 and is expected to grow to USD 2.86 billion in 2030.
AI Analysis | Feedback
Expected Drivers of Future Revenue Growth for AptarGroup (ATR) over the Next 2-3 Years:
- Growth in Proprietary Drug Delivery Systems: AptarGroup anticipates continued strong growth within its Pharma segment, specifically driven by its proprietary drug delivery systems for injectables, systemic nasal drug delivery, and consumer healthcare solutions. This segment is considered pipeline-driven, with recent years seeing a high number of new product launches and opportunities added to the pipeline, supporting a long-term core sales target of 7% to 11% growth. The demand for injectable components, notably those related to GLP-1 drug delivery systems, has shown significant increases, further bolstering this driver.
- Strategic Acquisitions and CDMO Expansion: AptarGroup is expanding its capabilities and market reach through strategic acquisitions. For example, the acquisition of Mod3 Pharma's clinical trial manufacturing capabilities in July 2025 significantly enhances Aptar's Contract Development and Manufacturing Organization (CDMO) services for early-stage drug development, including an FDA-inspected facility. Additionally, the planned finalization of the Somaplast acquisition in Brazil in Q4 2025 is expected to bolster its pharma segment further.
- Development and Commercialization of Digital Health Solutions: The company's collaborations, such as the partnership with Sonmol in China and other Asian markets, are focused on developing digital therapies and services platforms, particularly for respiratory diseases. This initiative aims to expand platform services for remote patient monitoring, improve patient and physician interactions, and enhance treatment adherence and outcomes. Aptar's strategic investment in Sonmol further extends its collaboration into precision micron-scale drug delivery.
- Integration of Ultra-Pure Recycled Polypropylene (UPRP) and Sustainability Initiatives: AptarGroup's strategic partnership with PureCycle Technologies is focused on developing and incorporating ultra-pure recycled polypropylene (UPRP) into dispensing applications. Products utilizing PureFive resin are projected to be in production by late 2025 and available in stores by early 2026. This collaboration, alongside Aptar's broader commitment to making its dispensing solutions 100% reusable, recyclable, or compostable by 2025, aligns with growing market demand for sustainable packaging and supports a circular economy.
- Launch of Innovative New Products: AptarGroup consistently drives growth through innovation and new product introductions across its segments. Examples include the recently developed Unidose single-use liquid nasal delivery system, which has been utilized in the first FDA-approved intranasal loop diuretic for heart failure, demonstrating Aptar's capability in complex therapeutic areas and expanding its addressable market. Another innovation is the exclusive agreement with Bausch + Lomb for its Beat the Blink eye care delivery system. The company's extensive patent portfolio, with over 7,300 patents and pending patents, underscores its innovation-led approach.
AI Analysis | Feedback
Share Repurchases
- AptarGroup recently authorized a new share repurchase program of up to $600 million, which replaces all previous authorizations.
- For the full year 2025, the company repurchased 2.7 million shares totaling $365 million, marking the highest repurchase amount in the past decade.
- In 2025, AptarGroup returned $486 million to shareholders through share repurchases and dividends.
Capital Expenditures
- Capital expenditures for the full year 2025 decreased year-over-year, representing approximately 7% of sales.
- Capital investments for 2026 are projected to be in the range of $260 million to $280 million.
- The primary focus of these capital expenditures is on efficiency, prioritization of high-return investments, particularly in high-return pharma projects.
Peer Outperformance in Metal, Glass & Plastic Containers
ATR has outperformed 50% of its 10 Metal, Glass & Plastic Containers peers over 5Y. Metal, Glass & Plastic Containers ranks 8th of 15 industries in Materials by median 5Y return. The sector’s gains have largely come from elsewhere.
Share of Metal, Glass & Plastic Containers constituents that ATR has outperformed, by holding period. Peers without a full price history over a given window are excluded from that window.
1Y
40%
of 10 industry peers · -3.2% return
3Y
50%
of 10 industry peers · 13.6% return
5Y
50%
of 10 industry peers · 8.3% return
No Metal, Glass & Plastic Containers peer with a comparable growth profile has beaten ATR by more than 20pp over 5Y.
Median price return by industry across the Materials sector, ranked by 5Y. Metal, Glass & Plastic Containers is ATR's own industry. Use this to see which corners of the sector have carried the returns.
| Industry | Names | 1Y med | 3Y med | 5Y med | Top 3 by 5Y |
|---|---|---|---|---|---|
| Copper | 7 | 116.9% | 94.0% | 324.7% | COPR 1013% · TGB 454% · HBM 420% |
| Silver | 6 | 168.6% | 297.8% | 168.9% | HL 263% · SVM 211% · AYA 193% |
| Gold | 32 | 59.9% | 217.2% | 166.1% | IAG 796% · CNL 546% · KGC 502% |
| Steel | 13 | 25.8% | 50.1% | 119.0% | AMR 508% · HCC 498% · NWPX 317% |
| Aluminum | 3 | 97.7% | 133.2% | 52.2% | CENX 284% · KALU 52% · AA 33% |
| Diversified Metals & Mining | 24 | 12.3% | -0.4% | 50.3% | ATLX 237043% · USAR 64531% · FMST 1216% |
| Construction Materials | 7 | -13.9% | 34.2% | 46.4% | USLM 316% · CRH 95% · VMC 55% |
| Metal, Glass & Plastic Containers ← | 11 | 3.2% | 13.6% | 8.3% | KRT 169% · MYE 72% · GEF 69% |
| Precious Metals & Minerals | 9 | 46.4% | 157.6% | -0.7% | ASM 655% · PPTA 388% · ELE 120% |
| Paper & Plastic Packaging Products & Materials | 7 | 15.6% | 22.1% | -2.1% | PKG 99% · CCK 16% · SON 12% |
| Specialty Chemicals | 40 | 12.0% | 3.0% | -6.2% | LWLG 867% · ODC 480% · NEU 202% |
| Commodity Chemicals | 13 | 27.6% | 18.8% | -18.5% | HWKN 238% · MEOH 101% · LXU 69% |
| Diversified Chemicals | 4 | 5.7% | -26.4% | -23.7% | CBT 78% · ASH -5% · CC -42% |
| Fertilizers & Agricultural Chemicals | 10 | -4.4% | 3.4% | -32.4% | CF 221% · CTVA 106% · NTR 49% |
| Paper Products | 3 | -12.4% | -51.3% | -95.5% | CLW -30% · ITP -96% · MERC -96% |
Median of constituents with a full price history over each window. Top names are unfiltered by size in this render.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| AptarGroup Earnings Notes | 12/26/2025 | |
| AptarGroup Stock Looks Undervalued, Ready to Move Up? | 11/05/2025 | |
| How Low Can AptarGroup Stock Really Go? | 10/17/2025 | |
| AptarGroup vs Alphabet: Which Is A Better Investment? | 08/18/2025 | |
| AptarGroup vs Newmont: Which Is A Better Investment? | 08/18/2025 | |
| How Does AptarGroup Stock Stack Up Against Its Peers? | 08/13/2025 | |
| Better Bet Than ATR Stock: Pay Less Than AptarGroup To Get More From DIS, MRK | 08/12/2025 | |
| Better Bet Than ATR Stock: Pay Less Than AptarGroup To Get More From NEU | 08/12/2025 | |
| ARTICLES | ||
| Stocks Trading At 52-Week Low | 06/03/2026 | |
| Has AptarGroup Stock Quietly Become a Growth Opportunity? | 11/05/2025 |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 89.47 |
| Mkt Cap | 10.8 |
| Rev LTM | 7,071 |
| Op Inc LTM | 719 |
| FCF LTM | 396 |
| FCF 3Y Avg | 352 |
| CFO LTM | 652 |
| CFO 3Y Avg | 680 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 11.4% |
| Rev Chg 3Y Avg | 5.2% |
| Rev Chg Q | 10.3% |
| QoQ Delta Rev Chg LTM | 2.4% |
| Op Inc Chg LTM | 9.9% |
| Op Inc Chg 3Y Avg | 9.4% |
| Op Mgn LTM | 11.0% |
| Op Mgn 3Y Avg | 11.3% |
| QoQ Delta Op Mgn LTM | -0.1% |
| CFO/Rev LTM | 11.3% |
| CFO/Rev 3Y Avg | 11.9% |
| FCF/Rev LTM | 6.5% |
| FCF/Rev 3Y Avg | 7.1% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 10.8 |
| P/S | 1.0 |
| P/Op Inc | 9.3 |
| P/EBIT | 9.8 |
| P/E | 18.5 |
| P/CFO | 9.9 |
| Total Yield | 7.5% |
| Dividend Yield | 1.7% |
| FCF Yield 3Y Avg | 5.8% |
| D/E | 0.6 |
| Net D/E | 0.5 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | 4.8% |
| 3M Rtn | 19.0% |
| 6M Rtn | 2.1% |
| 12M Rtn | 19.2% |
| 3Y Rtn | 17.1% |
| 1M Excs Rtn | 1.2% |
| 3M Excs Rtn | 17.2% |
| 6M Excs Rtn | -9.0% |
| 12M Excs Rtn | 0.3% |
| 3Y Excs Rtn | -55.9% |
Comparison Analyses
Segment Financials
Revenue by Segment| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Pharma | 1,738 | 1,644 | 1,522 | 1,372 | 1,298 |
| Beauty | 1,338 | 1,253 | 1,297 | 1,246 | 1,204 |
| Closures | 737 | 722 | 707 | 748 | 768 |
| Intersegment Sales | -36 | -36 | -39 | -44 | -44 |
| Total | 3,777 | 3,583 | 3,487 | 3,322 | 3,227 |
| $ Mil | 2015 | 2008 | 2005 | 2004 | 2003 |
|---|---|---|---|---|---|
| Aptar Pharma | 211 | 127 | |||
| Beauty & Home | 99 | 92 | |||
| Food and Beverage | 43 | ||||
| elimination | -28 | ||||
| Closures | 45 | ||||
| Other | -37 | ||||
| Dispensing Systems | 153 | 143 | 126 | ||
| SeaquistPerfect | 21 | 18 | 15 | ||
| Corporate & Other | -18 | -16 | |||
| Total | 324 | 227 | 174 | 143 | 125 |
| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Pharma | 2,284 | 2,058 | 2,112 | 1,873 | 1,834 |
| Beauty | 1,692 | 1,392 | 1,412 | 1,399 | 1,371 |
| Closures | 799 | 746 | 766 | 780 | 819 |
| Corporate & Other | 478 | 236 | 162 | 152 | 118 |
| Total | 5,253 | 4,432 | 4,452 | 4,203 | 4,141 |
Price Behavior
Price Behavior
| Market Price | $134.80 | |
| Market Cap ($ Bil) | 8.6 | |
| First Trading Date | 04/23/1993 | |
| Distance from 52W High | -6.8% | |
| 50 Days | 200 Days | |
| DMA Price | $128.64 | $124.93 |
| DMA Trend | indeterminate | up |
| Distance from DMA | 4.8% | 7.9% |
| 3M | 1YR | |
| Volatility | 22.9% | 24.6% |
| Downside Capture | -24.28 | 30.89 |
| Upside Capture | 48.91 | 20.49 |
| Correlation (SPY) | 3.4% | 22.1% |
ATR Betas & Captures as of 7/31/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 0.09 | 0.03 | 0.09 | 0.68 | 0.49 | 0.62 |
| Up Beta | -2.55 | -0.61 | -0.18 | 1.06 | 0.97 | 0.80 |
| Down Beta | 0.57 | 0.56 | 0.58 | 1.04 | 0.64 | 0.55 |
| Up Capture | 127% | 52% | 19% | 43% | 10% | 21% |
| Bmk +ve Days | 11 | 22 | 35 | 67 | 138 | 427 |
| Stock +ve Days | 13 | 25 | 36 | 66 | 126 | 400 |
| Down Capture | 16% | -48% | -23% | 40% | 47% | 80% |
| Bmk -ve Days | 11 | 21 | 28 | 59 | 114 | 326 |
| Stock -ve Days | 9 | 18 | 27 | 59 | 125 | 350 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with ATR | |
|---|---|---|---|---|
| ATR | -3.1% | 24.5% | -0.18 | - |
| Sector ETF (XLB) | 20.6% | 17.9% | 0.90 | 52.3% |
| Equity (SPY) | 21.1% | 12.9% | 1.22 | 22.3% |
| Gold (GLD) | 37.5% | 28.8% | 1.10 | 14.5% |
| Commodities (DBC) | 43.2% | 20.2% | 1.66 | -27.8% |
| Real Estate (VNQ) | 12.9% | 13.8% | 0.64 | 47.9% |
| Bitcoin (BTCUSD) | -31.6% | 44.1% | -0.73 | 14.8% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with ATR | |
|---|---|---|---|---|
| ATR | 1.6% | 22.6% | 0.02 | - |
| Sector ETF (XLB) | 6.4% | 19.1% | 0.22 | 60.5% |
| Equity (SPY) | 12.9% | 17.2% | 0.57 | 51.7% |
| Gold (GLD) | 20.6% | 18.6% | 0.90 | 12.1% |
| Commodities (DBC) | 10.4% | 19.6% | 0.41 | 2.2% |
| Real Estate (VNQ) | 2.3% | 18.9% | 0.02 | 49.8% |
| Bitcoin (BTCUSD) | 10.4% | 52.8% | 0.38 | 20.6% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with ATR | |
|---|---|---|---|---|
| ATR | 7.3% | 22.2% | 0.30 | - |
| Sector ETF (XLB) | 10.3% | 20.7% | 0.44 | 61.0% |
| Equity (SPY) | 15.2% | 17.9% | 0.72 | 56.3% |
| Gold (GLD) | 12.7% | 16.2% | 0.64 | 7.8% |
| Commodities (DBC) | 8.0% | 18.0% | 0.36 | 9.4% |
| Real Estate (VNQ) | 5.0% | 20.7% | 0.20 | 52.5% |
| Bitcoin (BTCUSD) | 63.1% | 66.1% | 1.03 | 13.0% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Updated 8/10/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 7/30/2026 | 0.1% | 1.4% | |
| 4/30/2026 | -3.8% | 1.6% | -8.8% |
| 2/5/2026 | 8.3% | 13.3% | 7.9% |
| 10/30/2025 | -6.7% | -6.6% | -2.2% |
| 7/31/2025 | -10.0% | -10.6% | -11.4% |
| 5/1/2025 | 2.5% | 3.4% | 5.8% |
| 2/6/2025 | -8.5% | -8.7% | -3.8% |
| 10/24/2024 | 1.4% | 0.8% | 3.0% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 17 | 17 | 13 |
| # Negative | 7 | 7 | 10 |
| Median Positive | 2.2% | 2.2% | 5.6% |
| Median Negative | -6.2% | -6.6% | -2.7% |
| Max Positive | 8.3% | 13.3% | 11.8% |
| Max Negative | -10.0% | -10.6% | -11.4% |
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 7/30/2026 | 0.1% | 1.4% | |
| 4/30/2026 | -3.8% | 1.6% | -8.8% |
| 2/5/2026 | 8.3% | 13.3% | 7.9% |
| 10/30/2025 | -6.7% | -6.6% | -2.2% |
| 7/31/2025 | -10.0% | -10.6% | -11.4% |
| 5/1/2025 | 2.5% | 3.4% | 5.8% |
| 2/6/2025 | -8.5% | -8.7% | -3.8% |
| 10/24/2024 | 1.4% | 0.8% | 3.0% |
| 7/25/2024 | 3.7% | 3.9% | 6.3% |
| 4/25/2024 | 2.2% | 4.1% | 5.6% |
| 2/8/2024 | 5.2% | 2.2% | 8.0% |
| 10/25/2023 | 0.9% | 0.5% | 5.0% |
| 7/27/2023 | 3.9% | 1.4% | 7.1% |
| 4/27/2023 | 1.7% | 2.2% | -1.8% |
| 2/16/2023 | 5.4% | 3.7% | 1.9% |
| 10/27/2022 | 2.1% | -4.4% | 4.5% |
| 7/28/2022 | -0.1% | -1.3% | -3.2% |
| 4/28/2022 | 2.4% | 0.6% | -2.9% |
| 2/17/2022 | 2.4% | 4.6% | 2.6% |
| 10/28/2021 | -4.1% | 2.0% | -0.1% |
| 7/30/2021 | 0.8% | -0.1% | 5.2% |
| 4/30/2021 | 1.1% | 4.5% | -2.6% |
| 2/18/2021 | -6.2% | -7.6% | -1.2% |
| 10/29/2020 | 1.0% | 8.8% | 11.8% |
| SUMMARY STATS | |||
| # Positive | 17 | 17 | 13 |
| # Negative | 7 | 7 | 10 |
| Median Positive | 2.2% | 2.2% | 5.6% |
| Median Negative | -6.2% | -6.6% | -2.7% |
| Max Positive | 8.3% | 13.3% | 11.8% |
| Max Negative | -10.0% | -10.6% | -11.4% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 06/30/2026 | 07/31/2026 | 10-Q |
| 03/31/2026 | 05/01/2026 | 10-Q |
| 12/31/2025 | 02/06/2026 | 10-K |
| 09/30/2025 | 10/31/2025 | 10-Q |
| 06/30/2025 | 08/01/2025 | 10-Q |
| 03/31/2025 | 05/02/2025 | 10-Q |
| 12/31/2024 | 02/07/2025 | 10-K |
| 09/30/2024 | 10/25/2024 | 10-Q |
| 06/30/2024 | 07/26/2024 | 10-Q |
| 03/31/2024 | 04/26/2024 | 10-Q |
| 12/31/2023 | 02/09/2024 | 10-K |
| 09/30/2023 | 10/26/2023 | 10-Q |
| 06/30/2023 | 07/28/2023 | 10-Q |
| 03/31/2023 | 04/28/2023 | 10-Q |
| 12/31/2022 | 02/17/2023 | 10-K |
| 09/30/2022 | 10/28/2022 | 10-Q |
| Report Date | Filing Date | Filing |
|---|---|---|
| 06/30/2026 | 07/31/2026 | 10-Q |
| 03/31/2026 | 05/01/2026 | 10-Q |
| 12/31/2025 | 02/06/2026 | 10-K |
| 09/30/2025 | 10/31/2025 | 10-Q |
| 06/30/2025 | 08/01/2025 | 10-Q |
| 03/31/2025 | 05/02/2025 | 10-Q |
| 12/31/2024 | 02/07/2025 | 10-K |
| 09/30/2024 | 10/25/2024 | 10-Q |
| 06/30/2024 | 07/26/2024 | 10-Q |
| 03/31/2024 | 04/26/2024 | 10-Q |
| 12/31/2023 | 02/09/2024 | 10-K |
| 09/30/2023 | 10/26/2023 | 10-Q |
| 06/30/2023 | 07/28/2023 | 10-Q |
| 03/31/2023 | 04/28/2023 | 10-Q |
| 12/31/2022 | 02/17/2023 | 10-K |
| 09/30/2022 | 10/28/2022 | 10-Q |
| 06/30/2022 | 07/29/2022 | 10-Q |
| 03/31/2022 | 04/29/2022 | 10-Q |
| 12/31/2021 | 02/18/2022 | 10-K |
| 09/30/2021 | 10/29/2021 | 10-Q |
| 06/30/2021 | 07/30/2021 | 10-Q |
| 03/31/2021 | 04/30/2021 | 10-Q |
| 12/31/2020 | 02/19/2021 | 10-K |
| 09/30/2020 | 10/30/2020 | 10-Q |
| 06/30/2020 | 07/31/2020 | 10-Q |
| 03/31/2020 | 05/01/2020 | 10-Q |
| 12/31/2019 | 02/24/2020 | 10-K |
| 09/30/2019 | 11/01/2019 | 10-Q |
Recent Forward Guidance
Updated 7/31/2026Latest: Q2 2026 Earnings Reported 7/30/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| Q3 2026 Adjusted EPS | 1.45 | 1.49 | 1.53 | 9.6% | Higher New | Guidance: 1.36 for Q2 2026 | |
| Q3 2026 Effective Tax Rate | 22.5% | 23.5% | 24.5% | 0.0% | Same New | Guidance: 23.5% for Q2 2026 | |
Prior: Q1 2026 Earnings Reported 4/30/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| Q2 2026 Adjusted EPS | 1.32 | 1.36 | 1.4 | 16.2% | Higher New | Guidance: 1.17 for Q1 2026 | |
| Q2 2026 Effective Tax Rate | 22.5% | 23.5% | 24.5% | ||||
Q4 2025 Earnings Reported 2/5/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| Q1 2026 Adjusted EPS | 1.13 | 1.17 | 1.21 | -5.6% | Lower New | Guidance: 1.24 for Q4 2025 | |
| 2026 Capital Expenditures | 260.00 Mil | 270.00 Mil | 280.00 Mil | ||||
Q3 2025 Earnings Reported 10/30/2025
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| Q4 2025 Adjusted EPS | 1.2 | 1.24 | 1.28 | -21.0% | Lower New | Guidance: 1.57 for Q3 2025 | |
| 2025 Pharma Pipeline Contribution | 0.07 | 0.09 | 0.1 | ||||
| 2025 Emergency-use delivery systems sales | 0.05 | ||||||
Insider Activity
Updated 8/5/2026| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Prieur, Marc | Segment President | Direct | Sell | 8052026 | 136.26 | 3,500 | 476,897 | 2,155,983 | Form |
| 2 | Tanda, Stephan B | President and CEO | Direct | Sell | 8042026 | 136.16 | 9,838 | 1,339,588 | 32,506,463 | Form |
| 3 | Tlili, Hedi | Segment President | Direct | Sell | 8032026 | 135.00 | 8,854 | 1,195,290 | 2,076,165 | Form |
| 4 | Prieur, Marc | Segment President | Direct | Sell | 6102026 | 115.58 | 5,000 | 577,895 | 2,233,332 | Form |
| 5 | Vinczeller, Shiela | Chief Human Resources Officer | Direct | Sell | 6052026 | 112.61 | 3,555 | 400,341 | 3,049,351 | Form |
| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Prieur, Marc | Segment President | Direct | Sell | 8052026 | 136.26 | 3,500 | 476,897 | 2,155,983 | Form |
| 2 | Tanda, Stephan B | President and CEO | Direct | Sell | 8042026 | 136.16 | 9,838 | 1,339,588 | 32,506,463 | Form |
| 3 | Tlili, Hedi | Segment President | Direct | Sell | 8032026 | 135.00 | 8,854 | 1,195,290 | 2,076,165 | Form |
| 4 | Prieur, Marc | Segment President | Direct | Sell | 6102026 | 115.58 | 5,000 | 577,895 | 2,233,332 | Form |
| 5 | Vinczeller, Shiela | Chief Human Resources Officer | Direct | Sell | 6052026 | 112.61 | 3,555 | 400,341 | 3,049,351 | Form |
| 6 | Gong, Xiangwei | President, Asia | Direct | Sell | 5272026 | 116.13 | 4,200 | 487,765 | 1,251,233 | Form |
| 7 | Hudson, Irene Elizabeth | EVP and Chief Legal Officer | Direct | Sell | 5082026 | 123.43 | 1,264 | 156,012 | 182,673 | Form |
| 8 | Touya, Gael | Segment President | Direct | Sell | 2192026 | 141.35 | 3,500 | 494,739 | 3,952,679 | Form |
| 9 | Prieur, Marc | Segment President | Direct | Sell | 2112026 | 137.81 | 2,000 | 275,620 | 1,894,198 | Form |
| 10 | Ackerman, Daniel | Chief Accounting Officer | Direct | Sell | 12152025 | 121.23 | 15,000 | 1,818,435 | 3,589,227 | Form |
| 11 | Touya, Gael | Segment President | Direct | Sell | 9122025 | 136.12 | 2,500 | 340,298 | 4,282,716 | Form |
| 12 | Vinczeller, Shiela | Chief Human Resources Officer | Direct | Sell | 9082025 | 137.97 | 1,167 | 161,006 | 3,467,640 | Form |
Investor Activity (13F)
Updated Aug 23, 202613F holdings as of Mar 31, 2026 (Q1 2026)
Active managers (13F portfolio over $250M, at least 3 holdings) with a position over $5M that is either over 10% of their portfolio or held in a concentrated book of 50 or fewer total positions. Index/ETF, sovereign, bank, community-bank and charitable/donor-advised filers are excluded.
Industry Resources
| Materials Resources |
| Chemical & Engineering News (C&EN) |
| Mining.com |
| Plastics News |
| Metal, Glass & Plastic Containers Resources |
| Packaging Digest |
| Packaging World |
| Plastics Today |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.
Core Cache Last Updated: 8/22/2026